An investigation accomplished by Koehler in 2009 indicated that Gibberellic acid 1 and 9α‐H allogibberic acid 7 could modulate NF‐κB pathway activity and, consequently, they could be utilized for the therapy of several NF‐κB‐related diseases, for instance, cancer and autoimmune diseases.[45]. This evidence concerns the gene NFKB1 and autoimmune disease.